Indaptus Therapeutics, Inc. is a clinical stage biotechnology company focused on developing a novel systemically administered immunotherapy for cancer and viral infections. The company's technology employs attenuated non pathogenic Gram negative bacteria designed to activate both innate and adaptive immune responses without requiring a tumor antigen. Its lead candidate Decoy20 has undergone Phase 1 testing in advanced solid tumors and is being evaluated in combination with…
Indaptus Therapeutics, Inc. is a clinical stage biotechnology company focused on developing a novel systemically administered immunotherapy for cancer and viral infections. The company's technology employs attenuated non pathogenic Gram negative bacteria designed to activate both innate and adaptive immune responses without requiring a tumor antigen. Its lead candidate Decoy20 has undergone Phase 1 testing in advanced solid tumors and is being evaluated in combination with immune checkpoint inhibitors. The firm's research builds on over a century of immunotherapy science and aims to convert immunologically cold tumors into hot tumors through broad immune stimulation.
Indaptus Therapeutics generates its financial resources primarily through the sale of equity securities in public and private offerings. The company has raised capital via at the market offerings, registered direct placements, private placement convertible notes, and standby equity purchase agreements, which together have provided the funds needed to advance its preclinical and clinical programs. It does not yet have commercial product sales or licensing revenue.
Within the competitive landscape of immuno oncology Indaptus Therapeutics positions itself as a pioneer of a bacteria based approach that simultaneously engages multiple innate and adaptive immune pathways. Its competitors include large integrated biopharmaceutical firms such as Amgen Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Genentech Inc., GlaxoSmithKline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding Ltd, and Sanofi SA, which dominate approved checkpoint inhibitor and CAR T markets. The company's differentiation lies in its ability to deliver a systemic multi signal immunotherapy that can be combined with existing therapies and does not depend on tumor specific antigen presentation.
The company's intended customers are patients with advanced solid tumors who have exhausted standard treatment options as well as the oncology clinics hospitals and specialized cancer treatment centers that administer these therapies. No specific customer names are disclosed in the filing.